Attenuated francisella and methods of use

Details Attenuated francisella and methods of use Attenuated francisella and methods of use

2011-07-05

2011-07-05

Minnifield, N M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S234100, C424S093200, C435S252300

Reexamination Certificate

active

07972607

ABSTRACT:
Francisella tularensisis the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuatedFrancisellamutants that include functional deletions in one or more of the dsbB, FTT0742, pdpB, fumA, and carB genes. Also provided are immunogenic compositions that include the attenuated bacteria. Methods are provided for treatment using the attenuatedFrancisellamutants.

REFERENCES:
patent: 2010/0233211 (2010-09-01), Tempel et al.
patent: WO 2004/084935 (2004-10-01), None
patent: WO 2005/049791 (2005-06-01), None
Deng et al, Infection and Immunity, Jul. 2006, 74/7:4224-4236.
Qin et al, Infection and Immunity, Jul. 2008, 76/7:3086-3092.
Isherwood et al, Advanced Drug Delivery Reviews, 2005, 57:1403-1414.
Baker et al, Ann. N Y Acad., 2007, 1105:138-159.
Larsson et al, Nature Genetics, Feb. 2005, 37/2:153-159.
Tempel et al, Infection and Immunity, Sep. 2006, 74/9:5095-5105.
Brotcke et al., “Identification of Mg1A-Regulated Genes Reveals Novel Virulence Factors inFrancisella tularensis,” Infect. Immun. 74:6642-6655, 2006.
Gray et al., “The Identification of Five Genetic Loci ofFrancisella novicidaAssociated with Intracellular Growth,”FEMS Microbiol. Lett. 215:53-56, 2002.
Larsson et al., “The Complete Genome Sequence ofFrancisella tularensis, the Causative Agent of Tularemia,”Nature Genet. 37:153-159, 2005.
Schulert et al., “Francisella tularensisGenes Required for Inhibition of the Neutrophil Respiratory Burst and Intramacrophage Growth Identified by Random Transposon Mutagenesis of Strain LVS,”Infect. Immun. 77:1324-1336, 2009.
Weiss et al., “In Vivo Negative Selection Screen Identifies Genes Required forFrancisellaVirulence,”Proc. Natl. Acad. Sci. USA104:6037-6042, 2007.
Dennis et al., “Tularemia as a Biological Weapon,”JAMA285:2763-2773, 2001.
Ellis et al., “Tularemia,”Clin. Microbiol.Rev. 15:631-646, 2002.
Golovliov et al., “A method for allelic replacement in Francisella tularensis,” FEMS Microbiol. Lett. 222:273-280, 2003.
Havlasová et al., “Mapping of Immunoreactive Antigens ofFrancisella tularensisLive Vaccine Strain,”Proteomics2:857-867, 2002.
Kawula et al., “Use of Transposon-Transposase Complexes to Create Stable Insertion Mutant Strains ofFrancisella tularensisLVS,”Appl. Environ. Microbiol. 70:6901-6904, 2004.
Krakauer, “Levels of Interleukin 6 and Tumor Necrosis Factor in Serum from Humans Vaccinated with Live, AttenuatedFrancisella tularensis,” Clin. Diagn. Lab. Immunol. 2:487-488, 1995.
Nano et al., “AFrancisella tularensisPathogenicity Island Required for Intramacrophage Growth,”J. Bacteriol. 186:6430-6436, 2004.
Oyston and Quarry, “Tularemia Vaccine: Past, Present and Future,” Antonie van Leeuwenhoek 87:277-281, 2005.
Shen et al., “Mice Sublethally Infected withFrancisella novicidaU112 Develop Only Marginal Protective Immunity Against Systemic or Aerosol Challenge With Virulent Type A or B Strains ofF. tularensis,” Microbial. Pathogenesis37:107-110, 2004.
Tempel et al., “F. novicidaTransposon Mutants Attenuated for Growth in Macrophages and Mice,” Oral presentation in Canada for the Pacific Northwest Meeting on Tularemia, Aug. 19, 2005.
Tempel et al., “FrancisellaTransposon Mutants Attenuated in Macrophages Protect Against Wild-Type Challenge in Mice,” Oral presentation in Sweden, Nov. 25-30, 2005.
Tempel et al., “FrancisellaTransposon Mutants Attenuated in Macrophages Protect Against Wild-Type Challenge in Mice,” Poster presentation at Woods Hole, MA, Nov. 1-4, 2006.
Tempel et al., “FrancisellaTransposon Mutants Attenuated in Macrophages Protect Against Wild-Type Challenge in Mice,” Poster presentation at Jiminy Peak Resort, MA, Nov. 6-8, 2005.
Tempel et al., “AttenuatedFrancisella novicidaTransposon Mutants Protect Mice Against Wild-Type Challenge,”Infect. Immun. 74:5095-5105, 2006.
Twine et al., “A Mutant ofFrancisella tularensisStrain SCHU S4 Lacking the Ability to Express a 58-Kilodalton Protein is Attenuated for Virulence and Is an Effective Live Vaccine,”Infect. Immun. 73:8345-8352, 2005.
Wu et al., “Intranasal Vaccination Induces Protective Immunity against Intranasal Infection with VirulentFrancisella tularensisBiovar A,”Infect. Immun. 73:2644-2654, 2005.
Tularemia Workshop 2005 Program, Nov. 6-8, 2005, Jiminy Peak Mountain Resort, Hancock, MA.
Tularemia from Wikipedia, Dec. 9, 2005.

Affiliated with

Also associated with

Rating

Attenuated francisella and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuated francisella and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated francisella and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2647702